Boston Scientific
-
BioPharma, Devices & Diagnostics, Health Tech
7 JPM Announcements You Don’t Want to Miss
This year’s J.P. Morgan Healthcare Conference brought a bevy of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for seven of the event’s most notable announcements.
-
Boston Scientific Continues Buying Spree with $3.7B Axonics Acquisition
Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $3.7 billion. Experts agree that this deal will make a profitable impact on Boston Scientific’s urology business.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
FDA to review data on stroke-prevention implants after study finds more adverse events in women
A study published in August found that women experienced more adverse events from Boston Scientific’s Watchman implant than men. The FDA said it plans to take a closer look at data for these stroke-prevention implants, but still says the benefits outweigh the risks.
-
Abbott takes on competition with FDA approval of device to prevent afib-related strokes
Abbott Laboratories received FDA approval for its Amulet device to treat people with atrial fibrillation who are at risk of ischemic stroke. The device would go head-to-head with one developed by Boston Scientific that was approved in 2015.
-
Devices & Diagnostics, Health Tech
Boston Scientific to acquire cardiac monitoring company Preventice for $925M
Boston Scientific will acquire remote cardiac monitoring company Preventice for $925 million in cash and up to $300 million in milestone payments. The deal is expected to close in mid-2021.
-
Startups, Devices & Diagnostics
Boston Scientific completes Millipede acquisition for $325 million
Earlier this year, the Marlborough, Massachusetts-based medical device giant invested $90 million into Millipede with the option of acquiring the rest of the company,
-
Devices & Diagnostics, BioPharma, Pharma
Novartis, Gilead, Celgene/Agios blood cancer treatments sweep Prix Galien awards
Along with Boston Scientific’s Watchman in the technology category, Novartis and Gilead’s Kite shared the biotechnology award for CAR-T therapy, while Celgene/Agios’s Idhifa won the pharmaceutical prize.
-
Medtronic wins FDA nod to launch first MR-Conditional CRT pacemakers
Medtronic becomes the first in the U.S. to win FDA approval for a quadripolar cardiac resynchronization therapy pacemaker that is also safe to use under MRI if certain conditions are met.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
New Bos Sci acquisition raises question: Will the Lotus (valve) ever blossom?
Boston Scientific may have purchased Swiss structural heart company Symetis for many reasons but one could very well be that the Lotus aortic valve is not ready for prime time.
-
Bye bye device tax may not mean jobs galore
If one were to believe the device lobby, jobs would come roaring back once the device tax is permanently repealed. The reality is more complex.
-
Hospitals, Devices & Diagnostics
Boston Scientific aims to localize chemotherapy drugs to tackle liver cancer
Boston Scientific is testing microspheres coated with a chemotherapy drug that can be delivered at the tumor site in the liver to provide an alternative to chemotherapy drugs with its attendant side effects and costs.
-
Hospitals, Devices & Diagnostics
Boston Scientific acquires RF ablation firm to treat chronic pain
Cosman Medical, which makes RF generators and electrodes among other things, will become part of Boston Scientific’s neuromodulation business.
-
Boston Scientific gets FDA approval for pacemakers designed to safely undergo MR scans
With the full ImageReady system, patients are approved to get full-body MRI scans, which eliminates some of the potential risks of a device malfunctioning due to the scan.